NVE Corporation Earnings Call Transcripts
Fiscal Year 2027
-
Revenue and net income soared 81% and 79% year-over-year, fueled by strong product sales and new launches in robotics and medical devices. Leadership transition and board expansion signal strategic continuity, while robust margins and cash position support optimism for sustained growth.
Fiscal Year 2026
-
Quarterly net income rose 27% year-over-year, driven by strong non-defense product sales and lower expenses. Major expansion increased capacity, and management is optimistic about future growth in defense, R&D, and high-value markets like medical devices and robotics.
-
Q3 FY2026 saw 23% revenue growth and 11% higher net income, driven by broad-based sales and lower operating expenses, despite a lower gross margin and higher tax rate. New equipment and product launches support growth in medical and industrial markets.
-
Sequential revenue grew 4% on strong distributor and non-defense sales, while year-over-year revenue declined 6% due to lower contract R&D. Gross margin fell to 78%, net income dropped to $3.31M, and new products plus production expansion are expected to drive future growth.
-
Revenue and net income declined year-over-year due to lower defense sales, but distributor and non-defense sales improved as industry conditions stabilized. New sensor products and capital investments position the company for future growth, with sequential gains expected in defense-related business.
Fiscal Year 2025
-
Quarterly revenue grew 3% year-over-year and 44% sequentially, driven by a surge in contract R&D and product sales, with gross margin rising to 79%. Annual net income declined 12% due to earlier softness, but strong product launches and major CapEx are expected to drive future growth.
-
Earnings remained strong despite a 25% revenue decline, with gross margin rising to 84% due to higher direct sales and a favorable product mix. R&D investment and facility expansion support new product launches, while management is optimistic about improving industry conditions.
-
Quarterly revenue declined 5% year-over-year due to lower product sales, but gross margin rose to 86% and contract R&D revenue surged. Net income fell 15%, yet comprehensive income increased slightly. Management remains optimistic as inventory levels normalize and new products enter production.
-
Strong earnings and cash flow were achieved despite a 23% revenue decline, with gross margin rising to 86% and operating cash flow up 16%. Investments in advanced packaging and strong defense and electrification markets are expected to drive future growth.